Environmental factors affecting IBD Have we made progress? Peter Laszlo Lakatos 1st Department of Medicine Semmelweis University Budapest Hungary
|
|
- Steven Stone
- 5 years ago
- Views:
Transcription
1 Environmental factors affecting IBD Have we made progress? Peter Laszlo Lakatos 1st Department of Medicine Semmelweis University Budapest Hungary
2 Environmental factors in IBD Are associated with disease susceptibility? Predicting disease phenotype? During the course of the disease, are they of any value in predicting relapse? short-long term prognosis and risk for complications?
3 IBD a complex phenotype
4 Environmental factors in IBD flora stress smoking drugs (OC, NSAID) appendectomy IBD infections (measles, mycobacterium, pharyngitis, tonsillitis,) diet hygiene (refined sugar, fat, fast food, corn flakes, chocolate, cocacola, toothpaste)
5 Disease susceptibility
6 Diet? Evidence suggesting a relationship between sugars and onset of Crohn's disease was inconsistent and subject to important methodological limitations. There was a clear lack of distinction between reporting of current, as opposed to, retrospective intakes. There appeared to be no clinical advantage to the use of reduced sugar diets in Crohn's disease treatment Riordan AM Eur J Clin Nutr 1998;52:
7 Developed hygiene? Bernstein CN Am J GE 2006
8 Developed hygiene? Bernstein CN Am J GE 2006
9 Developed hygiene? OR for IBD 95%CI male gender urban environment number of siblings (1 vs 5 or more) higher birth order (5 or higher vs 1) Klement E Am J GE 2008
10 Baron S Gut 2005 Developed hygiene?
11 Vaccination? Davis RL Arch Ped Adolesc Med 2001
12 Drugs, oral contraceptive use Bernstein CN Am J GE 2006
13 Oral contraceptive use OR CD : 1.44, OR CD : 1.51, (14 studies) 95%CI: %CI: OR UC : 1.29, 95%CI: Godet PG Gut 1995 Cornish JA Am J GE 2008
14 Appendectomy and risk of UC Rate of appendectomy in UC: 1/174 (0.6%) Rate of appendecytomy in controls: 41/161 (25.4%) OR: 59.1 (95% CI, ) Rutgeerts NEJM 1994 Koutrobakis IBD 2002
15 Life events Lerebours E IBD 2007
16 Smoking
17 current vs never smoking %CI: P<0.001 former vs never smoking %CI: P=0.08 Mahid SS Mayo Clin Proc 2006
18 current vs never smoking %CI: P<0.001 former vs never smoking %CI: P<0.001 Mahid SS Mayo Clin Proc 2006
19 Passive childhood smoking Mahid SS IBD 2007
20 Is it infectious? Virus, bacteria or worms?
21 Dysbiosis in Crohn s disease? Faecal flora Bacteroides vulgatus Eubacteria Peptostreptococci Coprococci E.coli Bifidobacteria Lactobacilli
22 Mucosa associated bacteria are common in Crohn s disease 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% n = Asymptomatic controls Self-limiting colitis Intermediate colitis UC CD 54 In 40% CD patients > cfu/ml 0 <1000 cfu/μl 1000 <10000 cfu/μl <50000 cfu/μl >50000 cfu/μl Swidzsinski et al. Gastroenterology 2002
23 Cold chain is it a hypothesis? Epidemiological data allow assessment of familial environmental risk factors related to western lifestyle, diet, bacteria, and domestic hygiene. All findings point to refrigeration as a potential risk factor for Crohn s disease. Furthermore, cold-chain development paralleled the outbreak of Crohn s disease during the 20th century. The cold chain hypothesis suggests that psychrotrophic bacteria such as Yersinia spp and Listeria spp contribute to the disease. Hugot JP Lancet 2003
24 History of genetic research in IBD 1980 IBD is a (poly)genic and multifactorial disorder 1990 Genome-wide Linkage Scans Identification of susceptibility regions in CD Scepticism!!! 2001 NOD2/CARD15 CD becomes example of Success story Innate Immunity and Pattern Recognition Receptors Common pathways between inflammatory diseases 2006 Genome-wide Association Scans ATG16L1, IRGM, 24
25 Pattern recognition receptors (PRRs) Important role in innate immunity Recognition and response against Gramnegative bacteria Extracellular membrane bound, Toll Like Receptors (TLR) Intracellular in the cytosol, NOD2/CARD15 Some mutations predispose to bacterial infections, others to immune mediated diseases
26 Mucosa associated bacteria are common in Crohn s disease Barnich N World J GE 2007
27 Mucosa associated bacteria are common in Crohn s disease Darfeuille-Michaud A Gastroenterology 2004
28 But bacterial profile is not different between ulcerated and normal mucose in Crohn s disease dominant microbiotas do not differ qualitatively between ulcerated and nonulcerated mucosae. Biodiversity remains high in ulcerated mucosa. Vasquez N IBD 2007 Seksik J Clin Microbiol 2005
29 Trichuris suis in the treatment of IBD Summers RW Gut CD and 54 adult patients 2500 Trichuris suis ova/placebo every 2-3 w. for 12 w. Primary endpoint: CDAI<150 at week 24 improvement of UCDAI to 4 at 12 weeks Summers RW GE 2005
30 Predicting disease phenotype/disease course?
31 Indolent course Crohn s disease active 8% 48% inactive 44% D sis Years after diagnosis Munkholm P, et al. Scand J Gastroenterol 1995:30:
32 Aggressive course Crohn s disease active p < % 50% inactive D sis Years after diagnosis 5% Munkholm P, et al. Scand J Gastroenterol 1995:30:
33 Is diet predicting the relapse rate in UC? Jowett SL Gut 2004
34 Is diet predicting the relapse rate in UC? Jowett SL Gut 2004
35 Is education level associated with time to relapse in UC? Hoie O Am J GE 2007
36 Stress
37 Is stress associated with disease course in IBD?
38 Is stress associated with disease course in CD? Bitton Gut 2008
39 Is stress associated with disease course in CD? Bitton Gut 2008
40 Smoking is associated with probability of flares in CD Cosnes J Gastroenterology 2001
41 Smoking and disease phenotype in CD % without stricture % without complicated disease Aldhous M. Am J GE 2007
42 Association between smoking, azathioprine/biological use and need for surgery in patients with Crohn`s disease 1,0 0,8 no IM / no smoking IM / no smoking no IM / smoking IM / smoking censored censored censored censored Survival without surgery 0,6 0,4 0,2 0,0 0,00 50,00 100,00 150,00 200,00 250,00 300,00 follow-up (months) plogrank<0.001, pbreslow<0.001 Szamosi T ECCO 2009
43 Summary of cox model: factors affecting time to first surgery Gender Disease location p Hazard Ratio 95%CI L L L3 Disease behavior <0.001 reference B1 < B B3 Smoking / Azathioprine-biological use <0.001 reference noaza-biological/no smoking AZA-biological/no smoking noaza-biological/smoking < AZA-biological/ smoking reference Szamosi T ECCO 2009
44 Smoking and disease phenotype in UC Aldhous M. Am J GE 2007
45 Association between smoking and colectomy in UC OR: 0.57 (95%CI: ) Cosnes J Best Pract Res Clin GE 2004
46 Association between smoking and colectomy in UC 1,0 0,8 Survival without colectomy 0,6 0,4 0,2 0,0 no-smoking smoking censored censored 0,00 100,00 200,00 300,00 400,00 Szamosi T ECCO 2009 follow-up (months) plogrank=0.042, pbreslow=0.08
47 Appendectomy and disease course in UC Cosnes J Gut 2002
48 Environmental factors in IBD Disease susceptibilty: Conclusions Evidence supports the association between early life hygene, some dietary factors, smoking, appendectomy and oral contraceptive use (in females) and the development of IBD The role for dysbiosis or a specific infectious agent in the disease susceptibility is controversial Prediction of disease phenotype&course: Smoking is associated with relapse rate, change in disease behavior /extent and risk for surgery/colectomy Appendectomy seems to be preventive against colectomy Studies indicate that chronic stress, adverse life events, and avoidance coping can cause relapse in patients with IBD.
Environmental exposure: can we reduce risk?
Oxford Inflammatory Bowel Disease MasterClass Environmental exposure: can we reduce risk? Dr Peter Lakatos, Budapest, Hungary Oxford Inflammatory Bowel Disease MasterClass Environmental exposure: can we
More informationGenetic and Environmental Risks for IBD
Genetic and Environmental Risks for IBD CCFA April 26, 2014 Presented by: Name goes here April 30, 2014 TheoTheodore 1 Genetic and Environmental Risks for IBD Theodore M. Bayless, M.D. Director Emeritus
More informationWhat is IBD and Why Me?
Johns Hopkins Symposium: An Integrative Medicine Approach to Inflammatory Bowel Disease (IBD) What is IBD and Why Me? Steven R. Brant, M.D. Associate Professor of Medicine Director, Meyerhoff Inflammatory
More informationGenetics of Pediatric Inflammatory Bowel Disease
Genetics of Pediatric Inflammatory Bowel Disease Judith Kelsen MD Assistant Professor of Pediatrics Division of Gastroenterology, Hepatology, and Nutrition IBD Education Day 2/9/2014 Objectives Brief overview
More informationInflammatory Bowel Disease A model for translational medicine. D P Jewell Professor Emeritus of Gastroenterology University of Oxford
Inflammatory Bowel Disease A model for translational medicine D P Jewell Professor Emeritus of Gastroenterology University of Oxford Samuel Wilks 1859, Pathological Treatises of Guy s Hospital The London
More informationInflammatory Bowel Diseases (IBD) Clinical aspects Nitsan Maharshak M.D., IBD Center, Department of Gastroenterology and Liver Diseases Tel Aviv Soura
Inflammatory Bowel Diseases (IBD) Clinical aspects Nitsan Maharshak M.D., IBD Center, Department of Gastroenterology and Liver Diseases Tel Aviv Sourasky Medical Center Tel Aviv, Israel IBD- clinical features
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More informationCauses of IBD: The Role of Genetics and Microbes and the Epidemiology of IBD
Causes of IBD: The Role of Genetics and Microbes and the Epidemiology of IBD James D. Lewis, MD, MSCE Professor of Medicine and Epidemiology Perelman School of Medicine at the University of Pennsylvania
More informationGut Microbiota and IBD. Vahedi. H M.D Associate Professor of Medicine DDRI
Gut Microbiota and IBD Vahedi. H M.D Associate Professor of Medicine DDRI 1393.3.1 2 GUT MICROBIOTA 100 Trillion Microbes - 10 times more than cells in our body Collective weight of about 1kg in human
More informationDisease behavior in adult patients- are there predictors for stricture or fistula formation?
Disease behavior in adult patients- are there predictors for stricture or fistula formation? Falk Symposium 168, Madrid, Spain Iris Dotan, M.D., Head, IBD Center, Department of Gastroenterology and Liver
More informationAnti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis
Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis University, 1st Department of Medicine Budapest June 13-15,
More informationCrohn s Disease. Naturopathic Treatment Options
Crohn s Disease Naturopathic Treatment Options by Dr. Gayamali Karunaratna, B.Sc., M.Ed., ND Markham Natural Health Centre 3160 Steeles Avenue East, Suite 204 Markham, Ontario L3R 4G9 http://www.markhamnaturalhealthcentre.com
More informationIBD high risk groups
IBD high risk groups Ulcerative colitis Value (95% CI) CRC prevalence (%) 3.7 (3.2-4.2) Overall annual CRC incidence (%) 0.3 (0.2-0.4) Annual CRC incidence in first decade of UC (%) 0.2 (0.1-0.2) Annual
More informationEpidemiology of Inflammatory Bowel Disease and Overview of Pathogenesis
Epidemiology of Inflammatory Bowel Disease and Overview of Pathogenesis Crohn s disease (CD) and ulcerative colitis (UC) are believed to affect approximately 1.4 million people in the United States (US).
More informationCan We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA
Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA Endpoints Overview Hospitalization Surgery Colorectal cancer
More informationEpidemiology of Inflammatory Bowel Disease
Epidemiology of Inflammatory Bowel Disease Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota, U.S.A. 2010 MFMER slide-1 Loftus
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationIssues at Hand. Inflammatory Bowel Disease Paradigm. Diet changes the fecal microbiome. Experience with diet in IBD
Diet s Role in IBD David Suskind M.D. Professor of Pediatrics Director of Clinical Gastroenterology Division of Gastroenterology University of Washington Seattle Children s Hospital Issues at Hand Inflammatory
More informationDietary Options for Inflammatory Bowel Disease
Dietary Options for Inflammatory Bowel Disease Michael J. Rosen, MD, MSCI Schubert-Martin Inflammatory Bowel Disease Center Learning objectives Worldwide rise in the incidence of IBD The relationship between
More informationFactsheet - Risk factors for inflammatory bowel disease (IBD)
Key Points Knowledge of the causes or risk factors for Crohn s disease and ulcerative colitis is limited. Many genes have been shown to be associated with the development of IBD. Research is continuing
More informationZach Johnson---Masters Champion
Intestinal Helminths A New Approach to Therapy of Inflammatory Bowel Disease Douglas R. LaBrecque, MD Professor, Internal Medicine Director, Liver Service Univ. of Iowa Carver College of Medicine Zach
More informationIs there an anti-inflammatory diet in IBD?
CCFA North Texas Chapter IBD education symposium December 2, 2017, Dallas, TX Is there an anti-inflammatory diet in IBD? Themos Dassopoulos, MD Director, Baylor Scott and White Center for IBD Baylor University
More informationGuided by Dr. Michal Amitai Head of Abdominal Imaging Department of Diagnostic Imaging Sheba Medical Center Sackler School of Medicine, Tel Aviv
Guided by Dr. Michal Amitai Head of Abdominal Imaging Department of Diagnostic Imaging Sheba Medical Center Sackler School of Medicine, Tel Aviv University 1 SHARE study My year Collaboration between gastroenterology
More informationThe enteric microbiota: Implications for IBD. Eugene B. Chang, M.D. University of Chicago
The enteric microbiota: Implications for IBD Eugene B. Chang, M.D. University of Chicago On a per cell basis, humans are mostly prokaryote 100 90 80 70 60 50 40 30 20 10 0 EuK ProK The microbial flora
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationSignal Transduction in Inflammatory Bowel Disease
E v e n t s 0 6 4 Signal Transduction in Inflammatory Bowel Disease 0 1 2 3 4 1 0 1 0 1 0 1 0 1 0 F L 2 - H e ig h t Vineeta Khare Ph.D Overview Inflammatory Bowel Diseases 1. Epidemiology, Symptoms and
More informationStrategies for changing the course of Crohn s disease
Strategies for changing the course of Crohn s disease Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Where we are now and where we want to be Diagnosis (usually endoscopy)
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationRunning head: CHRON'S DISEASE GENE-ENVIRONMENTAL INTERACTION 1
Running head: CHRON'S DISEASE GENE-ENVIRONMENTAL INTERACTION 1 A review of Crohn's Disease Gene-Environmental Interaction A study of gene-environment interaction between genetic susceptibility variants
More informationTowards Precision Medicine in Inflammatory Bowel Diseases
Precision Medicine and Biomarkers Leaders Summit. Munich September 13-14, 2018 Towards Precision Medicine in Inflammatory Bowel Diseases ANDRÉS HURTADO-LORENZO, Ph.D. SENIOR DIRECTOR OF TRANSLATIONAL RESEARCH
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationCancer Risk with IBD Therapies How to Discuss with your Patients?
Cancer Risk with IBD Therapies How to Discuss with your Patients? Douglas L Nguyen, MD Assistant Clinical Professor of Medicine University of California, Irvine Medical Center H.H. Chao Comprehensive Digestive
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationMicrobiome GI Disorders
Microbiome GI Disorders Prof. Ram Dickman Neurogastroenterology Unit Rabin Medical Center Israel 1 Key Points Our gut microbiota Were to find them? Symbiosis or Why do we need them? Dysbiosis or when things
More informationOur microbiome: The role of vital gut bacteria, diet, nutrition and obesity
Our microbiome: The role of vital gut bacteria, diet, nutrition and obesity Prof Kevin Whelan Professor of Dietetics King s College London @ProfWhelan #BSG2017 Speaker Declarations This presenter has the
More informationNON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente
NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND Fabrizio Parente Gastrointestinal Unit, A.Manzoni Hospital, Lecco & L.Sacco School of Medicine,University of Milan - Italy
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationESPEN Congress Lisbon 2015 NUTRITIONAL ISSUES IN CROHN'S DISEASE. The clash of generations: children are not small adults S.
ESPEN Congress Lisbon 2015 NUTRITIONAL ISSUES IN CROHN'S DISEASE The clash of generations: children are not small adults S. Kolacek (HR) Role of Nutrition in Children with CD Child is NOT a Little Adult
More informationUnderstanding clinical aspects of Crohn s disease and ulcerative colitis: Implications for the basic scientist
Understanding clinical aspects of Crohn s disease and ulcerative colitis: Implications for the basic scientist Scott Plevy, MD Associate Professor of Medicine, Microbiology & Immunology UNC School of Medicine
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationMaterials EXCLUSION CRITERIA INCLUSION CRITERIA
Bifidobacteria numbers in colon of children with inflammatory bowel disease (IBD). Gosiewski T 1, Kochan P 1,StrusM 1, Brzychczy-Wloch M 1, Drzewiecki A 1, Kowalska-Duplaga K 2, Wedrychowicz A 2, Jedynak-Wasowicz
More informationCommunicating with the IBD Patient: How to convey risks and benefits
Communicating with the IBD Patient: How to convey risks and benefits October 30, 2011 ACG Postgraduate Course National Harbor, Maryland Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationFructo-oligosaccharides in Crohn s disease: a prospective randomised double blind controlled trial
Fructo-oligosaccharides in Crohn s disease: a prospective randomised double blind controlled trial Principal investigator: Dr James Lindsay St Bartholomew's Hospital and The Royal London Hospital Queen
More informationDogma: no bacteria, no IBD!
MICROBIOMA E MICI Mariangela Allocca, MD, PhD IBD Center, Dept. of Gastroenterology Humanitas Research Hospital Rozzano, Milan, Humanitas Gradenigo, Turin, Italy Dogma: no bacteria, no IBD! Experimental
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationChapter 2 Environmental Factors in the Epidemiology of Inflammatory Bowel Disease
Chapter 2 Environmental Factors in the Epidemiology of Inflammatory Bowel Disease Morten H. Vatn Keywords Environment Geography Socioeconomy Nutrition Microbiology Pharmacology Smoking Risk factors Introduction
More informationSpeaker Introduction
Speaker Introduction Stephen B. Hanauer, MD Professor of Medicine and Clinical Pharmacology University of Chicago Pritzker School of Medicine Chief of Gastroenterology, Hepatology, and Nutrition University
More informationSlide 1. Slide 2 Learning outcomes. Slide 3. Year 1 MBChB Lecture 15 Introduction to the Gut Microbiota. The importance of microbiota
Slide 1 Year 1 MBChB Lecture 15 Introduction to the Gut Microbiota Professor Barry Campbell Gastroenterology Research Unit Cellular & Molecular Physiology, Institute of Translational Medicine bjcampbl@liv.ac.uk
More informationGenetics. Environment. You Are Only 10% Human. Pathogenesis of IBD. Advances in the Pathogenesis of IBD: Genetics Leads to Function IBD
Advances in the Pathogenesis of IBD: Genetics Leads to Function Pathogenesis of IBD Environmental Factors Microbes Scott Plevy, MD Associate Professor of Medicine, Microbiology & Immunology UNC School
More informationGut Microbiota in Inflammatory Bowel Disease
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2013.16.1.17 Pediatric Gastroenterology, Hepatology & Nutrition 2013 March 16(1):17-21 Review Article PGHN Gut Microbiota in Inflammatory
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationA Case of Inflammatory Bowel Disease
A Case of Inflammatory Bowel Disease Dr Barrie Rathbone www.le.ac.uk 26 year old Polish woman Admitted as emergency under surgeons RUQ and RIF pain Abdominal pain had occurred intermittently for a few
More informationAccepted Manuscript. Does eradication of Helicobacter pylori cause inflammatory bowel disease? Johan Burisch, Tine Jess
Accepted Manuscript Does eradication of Helicobacter pylori cause inflammatory bowel disease? Johan Burisch, Tine Jess PII: S1542-3565(19)30153-3 DOI: https://doi.org/10.1016/j.cgh.2019.02.013 Reference:
More information4/17/2019 DISCLOSURES OBJECTIVES GI MICROBIOME & HEALTH: A REVIEW. Nancy C. Kois, MD, FCAP Contemporary Pathology Services. There are no disclosures
GI MICROBIOME & HEALTH: A REVIEW Nancy C. Kois, MD, FCAP Contemporary Pathology Services DISCLOSURES There are no disclosures OBJECTIVES Definitions: GI microbiota, GI microbiome, probiotic, prebiotic
More informationEast west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort
East west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort diseasespictures.com Balazs Radnai and Martin Eigler Statistik II. Course 27.01.2014. Introduction
More informationOptimizing Immunomodulators and
Optimizing Immunomodulators and Biologics i in Inflammatory Bowel Disease Sunanda Kane, MD, MSPH, FACG Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota,
More informationThe future of IBD therapeutic research
The future of IBD therapeutic research Jean-Frederic Colombel, MD Director Susan and Leonard Feinstein IBD Clinical Center Icahn School of Medicine, Mount Sinai Hospital New York J-F Colombel has served
More informationIBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital
IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital Aims To understand the aetiology of IBD To understand the impact that
More informationCrohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?
Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic
More informationProtocol for the management of acute severe ulcerative colitis in children
Protocol for the management of acute severe ulcerative colitis in children Introduction: Paediatric UC is severe and more extensive than adult onset UC with 6-8% presenting as pancolitis (1,2) Within five
More informationGut Lung Axis Implication of the Gut Microbiota beyond its niche
Gut Lung Axis Implication of the Gut Microbiota beyond its niche Reema Subramanian PhD Candidate (4 th year) Supervisor: Prof. Margaret Ip Department of Microbiology, CUHK Joint Graduate Student Seminar
More information1. Digestion of foods and absorption of nutrients takes place in stomach and small bowel in only 2-3 h.
1. Digestion of foods and absorption of nutrients takes place in stomach and small bowel in only 2-3 h. 2. The waste is then stored for 2 days in the large bowel. 3. Do modern humans need a large bowel?
More informationAzienda Ospedaliera S. Camillo Forlanini. Unità Operativa di Gastroenterologia. Moscow June Cosimo Prantera
/ Azienda Ospedaliera S. Camillo Forlanini Unità Operativa di Gastroenterologia Moscow June 2006 Cosimo Prantera ANTIBIOTICS AND BACTERIAL SPECIES Metronidazole Bacteroides - Clostridia Ciprofloxacin Escherichia
More informationPresence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation
ORIGINAL ARTICLE Annals of Gastroenterology (2019) 32, 1-6 Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation Dimitrios S. Politis a, Konstantinos
More informationInflammatory Bowel Disease Cohort Studies in Korea: Present and Future
SPECIAL REVIEW: IBD and Epidemiology in Asia ISSN 1598-9100(Print) ISSN 2288-1956(Online) http://dx.doi.org/10.5217/ir.2015.13.3.213 Intest Res 2015;13(3):213-218 Inflammatory Bowel Disease Cohort Studies
More informationImplementation of disease and safety predictors during disease management in UC
Implementation of disease and safety predictors during disease management in UC DR ARIELLA SHITRIT DIGESTIVE DISEASES INSTITUTE SHAARE ZEDEK MEDICAL CENTER JERUSALEM Case presentation A 52 year old male
More informationLooking for Answers. IBD Research March 9, Dr. Benjamin Click, MD MS Associate Staff Cleveland Clinic
Looking for Answers IBD Research 2019 March 9, 2019 Dr. Benjamin Click, MD MS Associate Staff Cleveland Clinic Disclosures No relevant financial disclosures There is still no cure for IBD Why me? ETIOLOGY
More informationPage 1. Global trends in diet parallel IBD. Is there an anti-inflammatory diet for IBD? Patients want to know. Challenges in establishing causality
Is there an anti-inflammatory diet for IBD? Why diet? Global trends in diet parallel IBD Ashwin N Ananthakrishnan, MD, MPH Director, Crohn s and Colitis Center Assistant Professor of Medicine Massachusetts
More informationAgenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationUNDERSTANDING CROHN S DISEASE
UNDERSTANDING CROHN S DISEASE START YOUR JOURNEY TOWARD UNDERSTANDING INFLAMMATORY BOWEL DISEASE CONTENTS INTRODUCTION 4 WHAT IS CROHN S DISEASE? 6 Symptoms of Crohn s disease 6 WHAT CAUSES CROHN S DISEASE?
More informationAli Keshavarzian MD Rush University Medical Center, Chicago, IL
Ali Keshavarzian MD Rush University Medical Center, Chicago, IL Ulcerative colitis Crohn s disease Optimize Quality of Life Induce remission [treat flare up] Maintain remission [avoid flare up] Prevent
More informationSelective leucocyte trafficking inhibitors for treatment of IBD
Selective leucocyte trafficking inhibitors for treatment of IBD Séverine Vermeire MD, PhD Department of Gastroenterology University Hospitals Leuven Belgium Migration of Leucocytes plays a key role in
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationIBD Case Studies. David Rowbotham. Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital
IBD Case Studies David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust
More informationMicrobiome in You: Optimizing Gut Bacteria for Better IBD Management
Microbiome in You: Optimizing Gut Bacteria for Better IBD Management KT Park, M.D., M.S. Assistant Professor Co-Director, Stanford Children s Inflammatory Bowel Disease Center Stanford University School
More informationProbiotics in the ICU. Who could benefit? Nadia J van Rensburg RD(SA) Groote Schuur Hospital, Cape Town
Probiotics in the ICU. Who could benefit? Nadia J van Rensburg RD(SA) Groote Schuur Hospital, Cape Town Outline Introduction: a brief overview Probiotics: Current guidelines Reviews and Meta-analyses IBD
More informationDr David Epstein Vincent Pallotti Hospital and University of Cape Town
Inflammatory Bowel Disease Management in South Africa in 2016 Pharmaceutical Care Management Association Dr David Epstein Vincent Pallotti Hospital and University of Cape Town Inflammatory Bowel Disease
More informationSarkis K Mazmanian, California Institute of Technology
Sarkis K Mazmanian, California Institute of Technology The human microbiota The human gut harbors 10 11-10 12 bacteria per gram colonic content (>10 14 total bacteria) Total bacteria outnumber human cells
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationAchieving Success in Ulcerative Colitis: the Role of Infliximab
Achieving Success in Ulcerative Colitis: the Role of Infliximab Dr Gill Watermeyer IBD clinic Groote Schuur Hospital 17 th August 2012 Inflammatory Bowel Disease Crohn s disease and ulcerative colitis
More informationNutrition as primary therapy in IBD. Dr Clare Donnellan Leeds General Infirmary
Nutrition as primary therapy in IBD Dr Clare Donnellan Leeds General Infirmary Case GB 34 year old female Diagnosed with Crohn s in 2002? Extent Offered steroids or surgery Declined both GB Represented
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationCOPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
More informationInfliximab (Remicade) for paediatric ulcerative colitis - second line
Infliximab (Remicade) for paediatric ulcerative colitis - second line September 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More information10/11/2010. Jonathan Braun, MD, PhD David Geffen School of Medicine at UCLA CCFA National Scientific Advisory Committee
Jonathan Braun, MD, PhD David Geffen School of Medicine at UCLA CCFA National Scientific Advisory Committee 1 Crohn s Disease Chronic disease of the intestines Sores (ulceration), perforation, scaring,
More informationGenetic Susceptibility. Objectives. What Causes IBD? Inflammatory Bowel Disease
4:45 5:30 pm IBD in Pediatrics SPEAKER Jennifer Strople, MD Presenter Disclosure Information The following relationships exist related to this presentation: Jennifer Strople, MD: Speakers Bureau for AbbVie
More informationOptimizing Management using CRP, Fecal Calprotectin and Ferritin. Peter Laszlo Lakatos 1st Department of Medicine Semmelweis University Budapest
Optimizing Management using CRP, Fecal Calprotectin and Ferritin Peter Laszlo Lakatos 1st Department of Medicine Semmelweis University Budapest Objectives Overview of disease progression Old and new treatment
More informationSelby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
More informationFibrotic complications of inflammatory bowel disease
January 27th 2017, 8th Gastro Foundation Weekend for Fellows; Spier Hotel & Conference Centre, Stellenbosch Fibrotic complications of inflammatory bowel disease Gerhard Rogler, Department of Gastroenterology
More informationChallenges in IBD: The Post-Op IBD Patient: Preventing Pouchitis & Recurrence
Challenges in IBD: The Post-Op IBD Patient: Preventing Pouchitis & Recurrence Sharon Dudley-Brown, PHD, FNP-BC, FAAN Assistant Professor Johns Hopkins University Baltimore, MD sdudley2@jhmi.edu Disclosures
More information